CAR-T Cell Therapies From the Transfusion Medicine Perspective

Overview

Journal Transfus Med Rev

Specialty Hematology

Date 2016 Apr 13

PMID 27067907

Citations 27

Authors

Andrew Fesnak

ChieYu Lin

Don L Siegel

Marcela V Maus

Affiliations

Soon will be listed here.

Abstract

The use of chimeric antigen receptor (CAR)-T cell therapy for the treatment of hematologic malignancies has generated significant excitement over the last several years. From a transfusion medicine perspective, the implementation of CAR-T therapy as a potential mainstay treatment for not only hematologic but also solid-organ malignancies represents a significant opportunity for growth and expansion. In this review, we will describe the rationale for the development of genetically redirected T cells as a cancer therapeutic, the different elements that are required to engineer these cells, as well as an overview of the process by which patient cells are harvested and processed to create and subsequently validate CAR-T cells. Finally, we will briefly describe some of the toxicities and clinical efficacy of CAR-T cells in the setting of patients with advanced malignancy.

Citing Articles

Efficient manufacturing of CAR-T cells from whole blood: a scalable approach to reduce costs and enhance accessibility in cancer therapy.

Traynor R, Vignola I, Sarkar S, Prochazkova M, Cai Y, Shi R Cytotherapy. 2024; 27(3):400-409.

PMID: 39652017 PMC: 11810577. DOI: 10.1016/j.jcyt.2024.11.013.

Promises and challenges of a decentralized CAR T-cell manufacturing model.

Shah M, Krull A, ODonnell L, De Lima M, Bezerra E Front Transplant. 2024; 2:1238535.

PMID: 38993860 PMC: 11235344. DOI: 10.3389/frtra.2023.1238535.

Granulocyte Colony Stimulating Factor-Mobilized Peripheral Blood Mononuclear Cells: An Alternative Cellular Source for Chimeric Antigen Receptor Therapy.

Ballesteros-Ribelles A, Millan-Lopez A, Carmona-Luque M, Herrera C Int J Mol Sci. 2024; 25(11).

PMID: 38891957 PMC: 11171785. DOI: 10.3390/ijms25115769.

CAR-T cell manufacturing landscape-Lessons from the past decade and considerations for early clinical development.

Dias J, Garcia J, Agliardi G, Roddie C Mol Ther Methods Clin Dev. 2024; 32(2):101250.

PMID: 38737799 PMC: 11088187. DOI: 10.1016/j.omtm.2024.101250.

Aptamer-Based Chromatographic Methods for Efficient and Economical Separation of Leukocyte Populations.

Ling M, Cardle I, Song K, Yan A, Kacherovsky N, Jensen M ACS Biomater Sci Eng. 2023; 9(8):5062-5071.

PMID: 37467493 PMC: 11016351. DOI: 10.1021/acsbiomaterials.3c00651.

References

Oble D, Loewe R, Yu P, Mihm Jr M . Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun. 2009; 9:3. PMC: 2935762. View

Barrett D, Singh N, Liu X, Jiang S, June C, Grupp S . Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. Cytotherapy. 2014; 16(5):619-30. PMC: 3988256. DOI: 10.1016/j.jcyt.2013.10.013. View

Ferrante A, Thong Y . Optimal conditions for simultaneous purification of mononuclear and polymorphonuclear leucocytes from human blood by the Hypaque-Ficoll method. J Immunol Methods. 1980; 36(2):109-17. DOI: 10.1016/0022-1759(80)90036-8. View

Weiden P, Flournoy N, Thomas E, Prentice R, Fefer A, Buckner C . Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979; 300(19):1068-73. DOI: 10.1056/NEJM197905103001902. View

Elkord E, Williams P, Kynaston H, Rowbottom A . Human monocyte isolation methods influence cytokine production from in vitro generated dendritic cells. Immunology. 2005; 114(2):204-12. PMC: 1782075. DOI: 10.1111/j.1365-2567.2004.02076.x. View

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

Powell Jr D, Brennan A, Zheng Z, Huynh H, Cotte J, Levine B . Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program. Cytotherapy. 2009; 11(7):923-35. DOI: 10.3109/14653240903188921. View

James J, Vale R . Biophysical mechanism of T-cell receptor triggering in a reconstituted system. Nature. 2012; 487(7405):64-9. PMC: 3393772. DOI: 10.1038/nature11220. View

Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J . Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010; 24(6):1160-70. PMC: 2888148. DOI: 10.1038/leu.2010.75. View

10.

Lamers C, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C . Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013; 21(4):904-12. PMC: 5189272. DOI: 10.1038/mt.2013.17. View

11.

Schulz M, Bialleck H, Thorausch K, Bug G, Dunzinger U, Seifried E . Unstimulated leukapheresis in patients and donors: comparison of two apheresis systems. Transfusion. 2013; 54(6):1622-9. DOI: 10.1111/trf.12506. View

12.

Loaiza S, Haynes R, Bray E, Finn S, Rezvani K, Apperley J . Donor lymphocyte collections using the spectra Optia MNC version 5. Transfus Apher Sci. 2013; 48(2):171. DOI: 10.1016/j.transci.2013.02.022. View

13.

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

14.

Garcia-Pineres A, Hildesheim A, Williams M, Trivett M, Strobl S, Pinto L . DNAse treatment following thawing of cryopreserved PBMC is a procedure suitable for lymphocyte functional studies. J Immunol Methods. 2006; 313(1-2):209-13. DOI: 10.1016/j.jim.2006.04.004. View

15.

Huston J, Levinson D, Tai M, Novotny J, Margolies M, Ridge R . Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A. 1988; 85(16):5879-83. PMC: 281868. DOI: 10.1073/pnas.85.16.5879. View

16.

Stroncek D, Fellowes V, Pham C, Khuu H, Fowler D, Wood L . Counter-flow elutriation of clinical peripheral blood mononuclear cell concentrates for the production of dendritic and T cell therapies. J Transl Med. 2014; 12:241. PMC: 4173057. DOI: 10.1186/s12967-014-0241-y. View

17.

Davila M, Riviere I, Wang X, Bartido S, Park J, Curran K . Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6(224):224ra25. PMC: 4684949. DOI: 10.1126/scitranslmed.3008226. View

18.

Juillerat A, Marechal A, Filhol J, Valton J, Duclert A, Poirot L . Design of chimeric antigen receptors with integrated controllable transient functions. Sci Rep. 2016; 6:18950. PMC: 4707440. DOI: 10.1038/srep18950. View

19.

Bryn T, Yaqub S, Mahic M, Henjum K, Aandahl E, Tasken K . LPS-activated monocytes suppress T-cell immune responses and induce FOXP3+ T cells through a COX-2-PGE2-dependent mechanism. Int Immunol. 2007; 20(2):235-45. DOI: 10.1093/intimm/dxm134. View

20.

Levine B . T lymphocyte engineering ex vivo for cancer and infectious disease. Expert Opin Biol Ther. 2008; 8(4):475-89. DOI: 10.1517/14712598.8.4.475. View